On June 2, 2022 Kiyatec, a leader in functional precision oncology, reported that new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO (Free ASCO Whitepaper) 2022 (Press release, KIYATEC, JUN 2, 2022, View Source [SID1234615459]). As a first-time ASCO (Free ASCO Whitepaper) presenter and exhibitor, Kiyatec will present its Clinical Services and Drug Development Services capabilities at ASCO (Free ASCO Whitepaper)’s first-ever Innovation Hub at kiosk #IH01. The ASCO (Free ASCO Whitepaper) meeting will be held in Chicago June 3-7, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this updated cohort of 42 patients with high grade glioma, 3D Predict Glioma prospectively predicted patient response to standard of care temozolomide (TMZ), regardless of MGMT methylation status. In a subgroup analysis of the 23 MGMT unmethylated patients, test-predicted responders had a relative median progression-free survival advantage of 5.9 months versus test-predicted non-responders (p = 0.0018). This data provides additional evidence of 3D Predict Glioma predictivity and its potential to provide additional information for glioma patient treatment options including clinical trial enrollment, alternative therapies indicated for use in glioma or combination therapy with TMZ.
Kiyatec Chief Executive Officer Matthew Gevaert, PhD, said, "This enhanced cohort adds to our body of clinical evidence demonstrating the predictive insights 3D Predict Glioma can provide to neuro-oncologists planning treatment for glioblastoma patients. With it, we’ve advanced our mission is to disrupt cancer care by accurately predicting patient-specific response and non-response before treatment begins."
High grade gliomas, including glioblastoma, are among the most aggressive brain cancers, with patients exhibiting highly variable treatment responses in both newly diagnosed and recurrent disease. TMZ with radiation therapy is the guideline-directed standard of care in the newly-diagnosed setting, which has remained relatively unchanged for over 15 years despite variable patient responses.
Kiyatec’s ex vivo KIYA-Predict pre-clinical platform and 3D Predict clinical assays are leading the functional precision oncology space with published, clinically-correlated evidence to prospectively predict glioma patient therapeutic response prior to initiation of therapy.
Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis